ADELAIDE, Australia – Australian biopharmaceutical companies engaged in drug development shouldn't waste their time trying to build a flagship company in Australia, said Race Oncology Ltd. CEO Peter Molloy. Rather, they should focus on partnering with big pharma as early as possible, he told attendees of the Ausbiotech conference.